Polish Journal of Pharmacology 2000-01-01

Combined treatment with NMDA antagonist, CGP 37849, and sigma receptor agonists, SA4503 or DTG, decreases the neuroleptic-induced catalepsy in rats.

G Skuza

Index: Pol. J. Pharmacol. 52(4) , 313-6, (2000)

Full Text: HTML

Abstract

The obtained results indicate that joint administration of CGP 37849, a competitive NMDA receptor antagonist, and SA4503, a sigma1 (sigma1) receptor agonist or DTG, sigma 1/2 receptor agonist, evoked anticataleptic effect at doses which were ineffective when each of the compounds was given alone.

Related Compounds

  • CGP 37849

Related Articles:

Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins.

2003-05-01

[Kidney Int. 63(5) , 1764-75, (2003)]

GSA: behavioral, histological, electrophysiological and neurochemical effects.

2005-02-15

[Physiol. Behav. 84(2) , 251-64, (2005)]

Competitive NMDA receptor antagonists and agonists: effects on spontaneous alternation in mice exposed to cerebral oligemia.

2004-01-01

[Pol. J. Pharmacol. 56(1) , 59-66, (2004)]

CGP 37849 and CGP 39551: novel competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity.

1990-01-01

[Prog. Clin. Biol. Res. 361 , 421-7, (1990)]

NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice.

2008-01-01

[Pharmacol. Rep. 60(5) , 655-63, (2008)]

More Articles...